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Discovery  of  peptidic  anti-­myotoxins
More than 2.5 millions envenomations and 125.000 death occur each year due to snakebite [1]. Current antivenoms consist of immunoglobulines
derived from animals, and they are therefore associated with a high risk of adverse reactions in humans [2]. The use of synthetic peptidic antitoxins
may lead to safer and more effective antivenoms. This research reports the discovery of peptidic antitoxins against myotoxin II from B. asper.
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Figure 1. A) Bothrops asper [3]. B) Composition of the venom of B.
asper. Myotoxin II is a Phospolipases A2 (PLA2), responsible for the
myotoxic effects of the venom. 0
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Figure 2. Phage display selection. Up to a billion different phages are
tested for their ability to bind to the toxin. Unbound phages are washed
away, bound phages are isolated, amplified, and sequenced [4].
Illustration borrowed from Laustsen AH., with permission.
Figure 3. ELISA results of
monoclonal phages. The large
difference in absorbance between
toxin and control indicates that
the phages bind to myotoxin II.
Six phages were identified as the
most promising leads.
Figure 4. The DNA from the six phages were isolated
and sequenced, and models of the peptides were
constructed using PEP-­FOLD.
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Conclusion
Six peptides were
discovered that
showed binding to
myotoxin II. Further
work is required to
determine binding
affinity and inhibitory
effect.
